(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
29 August 2013 (29.08.2013)

WIPO | PCT

(10) International Publication Number
WO 2013/124286 A1

(51) International Patent Classification:
C07D 487/04 (2006.01) *A61P 17/04* (2006.01)
A61K 45/06 (2006.01)

(21) International Application Number:
PCT/EP2013/053319

(22) International Filing Date:
20 February 2013 (20.02.2013)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
61/601,902 22 February 2012 (22.02.2012) US

(71) Applicant: **LEO PHARMA A/S** [DK/DK]; Industriparken 55, DK-2750 Ballerup (DK).

(72) Inventors: **SØRENSEN, Morten, Dahl**; c/o LEO Pharma A/S, Industriparken 55, DK-2750 Ballerup (DK). **DI FABIO, Romani**; c/o Aptuit, Via Fleming 4, I-37121 Verona (IT). **POZZAN, Alfonso**; c/o Aptuit, Via Flemming 4, I-37121 Verona (IT). **CATALANI, Maria, Pia**; c/o Aptuit, Via Fleming 4, I-37121 Verona (IT). **BLADH, Haakon**; c/o LEO Pharma A/S, Industriparken 55, DK-2750 Ballerup (DK). **FELDING, Jakob**; c/o LEO Pharma A/S, Industriparken 55, DK-2750 Ballerup (DK).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— *with international search report (Art. 21(3))*

— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*

(54) Title: NOVEL NEUROKININ 1 RECEPTOR ANTAGONIST COMPOUNDS



(A)

(57) Abstract: The present invention relates to a compound according to formula (A) wherein n is 1 or 2; R1 and R2 are independently hydrogen, C_{1-4} alkyl, C_{1-4} haloalkyl, C_{1-4} alkoxy, CD3 or halogen; R3 is hydrogen, C(=O)OR7 or C_{1-4} alkyl optionally substituted with hydroxy or NR8R9; R4 is hydrogen or oxo; R5 and R6 are independently hydrogen, hydroxy, NR8R9, C(=O)R7, C(=O)OR7, C(=O)NR8R9, C_{1-4} alkyl, wherein said C_{1-4} alkyl is optionally substituted with hydroxy, NR8R9 or a 5- or 6-membered heterocyclic ring, wherein said 5- or 6-membered heterocyclic ring is optionally substituted with C_{1-4} alkyl or C(=O)R7; or R5 and R6, together with the carbon atom to which they are attached, form $=CH_2$ or a 5- or 6-membered heterocycloalkyl, wherein said heterocycloalkyl is optionally substituted with C_{1-4} alkyl; R7 is hydrogen or C_{1-4} alkyl; R8 and R9 are independently hydrogen or C_{1-4} alkyl, or R8 and R9, together with the nitrogen atom to which they are attached, form a 5- or 6-membered heterocyclic ring, or a pharmaceutically acceptable salt or solvate thereof. The invention relates further to intermediates for the preparation of said compounds, to said compounds for use in therapy, to pharmaceutical compositions comprising said compounds, to methods of treating or ameliorating pruritic dermal diseases or conditions with said compounds, and to the use of said compounds in the manufacture of medicaments.

WO 2013/124286 A1